Search Results

Japanese research team visualizes cellular metabolic changes during fracture healing using hyperpolarized MRI

August 21, 2026, Gifu Pharmaceutical University and Gifu University announced that a multi-institutional Japanese research team successfully visualized changes in the redox state of skeletal progenitor cells during fracture healing in living mice using hyperpolarized magnetic resonance imaging technology. The findings were published online on August 15, 2026, in the British academic journal *npj Imaging*. The study was led by Takuya Kubo, a graduate student in the Department of Pharmacology at Gifu Pharmaceutical University, Professor Eiichi Hinoi, and related research teams at Gifu University, in collaboration with the University of Tokyo, Osaka University, the Research Institute of National Rehabilitation Center for Persons with Disabilities, and other institutions. After a fracture occurs, a tissue called a...

2026-08-31

Chonnam National University Hospital in Hwasun, South Korea, Adopts Deepnoid's Chest X-ray AI Interpretation Solution "M4CXR"

Deepnoid announced on August 31 that it has signed a supply contract with Chonnam National University Hospital in Hwasun, South Korea, to provide the hospital with its AI-based chest X-ray preliminary opinion generation solution, M4CXR. This contract is part of the "AI Medical System Support Project for Regional Responsible Medical Institutions" promoted by the Ministry of Health and Welfare of South Korea. Chonnam National University Hospital in Hwasun plans to improve the work efficiency of medical staff in interpreting chest X-ray images and further enhance the quality of medical services through the introduction of M4CXR. A representative from the Hwasun branch of Chonnam National University Hospital stated that introducing a generative AI-based image interpretation support system is of great significance for improving the quality of public medical services...

2026-08-31

Assam, India, Plans to Introduce Proton Beam Therapy for Cancer Treatment at a Public Hospital

Cancer treatment capabilities in Assam, India, are set to be upgraded. Assam Chief Minister Himanta Biswa Sarma announced that the state cabinet has approved the introduction of a proton beam therapy system at Gauhati Medical College Hospital. Once the project is completed, Assam will become the third region in India to offer proton beam therapy, and the hospital will be the first public hospital in India to be equipped with this technology. Currently, proton beam therapy is already in use at the Tata Memorial Centre in Mumbai and the Apollo Proton Cancer Centre in Chennai. The facility planned at Gauhati Medical College Hospital will become the third such treatment center in India. Proton beam therapy is an advanced form of radiotherapy used to treat cancer and certain non-cancerous tumors. Unlike conventional radiation therapy, which typically uses X-rays, proton therapy delivers precise irradiation to the tumor area using high-energy positively charged particles—protons. As proton beams enter the body, they release energy, causing DNA damage to cells. Healthy cells generally possess some capacity for repair, whereas cancer cells are less able to repair themselves, thereby inhibiting their growth and proliferation and helping to destroy tumor tissue.

2026-08-31

Leo Cancer Care and GE HealthCare Announce Collaboration to Advance Upright Radiotherapy Workflow Integration

Leo Cancer Care recently announced a commercial collaboration with GE HealthCare, focusing on GE HealthCare's advanced imaging solutions and intelligent radiotherapy software, with plans to apply related technologies to Leo Cancer Care's future upright radiotherapy systems to streamline patient and data workflows from simulation to treatment delivery. Under the collaboration framework, the two parties will explore integration pathways between GE HealthCare's intelligent radiotherapy software iRT and Leo Cancer Care's future upright radiotherapy solutions. iRT is an AI-assisted software developed for radiotherapy settings, primarily used to connect information, workflows, and applications across different systems, helping healthcare institutions simplify complex processes, enable patients to enter radiotherapy more promptly, and reduce clinician burden.

2026-08-30

Blueprint for Proton Therapy Center in Southeastern Busan, South Korea Unveiled to Address Regional Gap in Cancer Treatment Resources

The blueprint for the proton therapy center at the Southeastern Regional Nuclear Medicine Center in Gijang-gun, Busan, South Korea, was recently unveiled. The project is expected to help bridge the gap in cancer treatment resources between the Seoul metropolitan area and non-capital regions, and to promote the application of proton accelerators in high-tech industries. According to information from Gijang-gun, Busan, and the Southeastern Regional Institute of Radiation Medicine on August 29, the Busan Institute of Science and Technology Higher Education recently published a service report titled "Establishment of Promotion Strategy and Implementation Plan for the Southeastern Proton Therapy Center," which includes the construction blueprint and feasibility analysis of the center. The Southeastern Regional Institute of Radiation Medicine is advancing related preparatory work in response to the research and development review by the Ministry of Science and ICT in the second half of this year...

2026-08-30

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Plans to Complete Development of First Domestic Proton Beam Therapy Cyclotron by 2027

Russian scientists plan to complete the development of the country's first domestically produced proton beam therapy cyclotron by 2027, with commissioning to begin in the same year. This progress was announced by Sergey Gertzog, CEO of the Russian National Institute of Electronics and Atomic Energy (NIIEFA), at the recent Technoprom forum held in Novosibirsk. A proton beam therapy cyclotron is a type of charged particle accelerator that uses magnetic and electric fields to accelerate protons to high-energy states, reaching speeds of one-half to two-thirds the speed of light. The accelerated proton beam can target cancerous tumor areas with relative precision for oncological treatment. According to the schedule outlined in Gertzog's report...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Russia and Egypt Plan to Cooperate on Construction of Nuclear Medicine Center and Radiopharmaceutical Plant

Alexey Likhachev, CEO of Rosatom, recently stated that Russia and Egypt are expanding cooperation in non-energy nuclear technologies, with one of Egypt's key priorities being the construction of a high-performance nuclear medicine center based on a research reactor. According to reports, the project will adopt a comprehensive approach, including a radiopharmaceutical production plant, isotope production facilities, and modern diagnostic systems based on PET and SPECT technologies. Some diagnostic systems will use Russian equipment. Once completed, the project is expected to conduct up to 30,000 diagnostic examinations annually and provide treatment services for 400 patients. Construction of the medical facility is expected to begin as early as 2027...

2026-08-28

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

Huzhou, Zhejiang Launches Phase I "Drug-Device Combination" Clinical Trial for the Province's First BNCT System

Recently, the Boron Neutron Tumor Treatment Center at Huzhou Hospital Affiliated to Zhejiang University School of Medicine has drawn attention with the introduction of the province's first Boron Neutron Capture Therapy (BNCT) system. Previously, the system had already initiated a Phase I BNCT drug-device combination clinical trial. According to the system developer, Huapeng Neutron Technology (Hangzhou) Co., Ltd., BNCT is a radiotherapy technique combining drugs and devices, with its core lying in the coordinated use of boron-containing drugs and neutron irradiation. After entering the human body, the boron-containing drug can be absorbed by tumor cells; subsequent neutron beam irradiation triggers a localized reaction to achieve targeted radiotherapy against tumor cells. Unlike conventional radiotherapy, which typically employs fractionated irradiation over a longer treatment course, BNCT emphasizes selective targeting of tumor cells, aiming to reduce damage to surrounding healthy tissues and lower radiotherapy-related side effects such as hair loss and immunosuppression.

2026-08-27

Moffitt Cancer Center in the U.S. Launches $600 Million Radiopharmaceutical Program

Moffitt Cancer Center in Tampa, Florida, recently announced the launch of a new radiopharmaceutical program, planning to accelerate radiopharmaceutical research, development, and clinical translation through a total infrastructure investment of $600 million. The program will be advanced at the Speros campus of Moffitt Cancer Center in Pasco County, Florida. The campus spans 775 acres, and the related investment will support the development of radiopharmaceutical research and development capabilities, including the construction of new radiochemistry laboratories within the Moffitt Discovery and Innovation Center, which opens this fall. The innovation center has a building area of approximately 255,000 square feet. The program funding will also support the planned comprehensive theranostics center...

2026-08-27

Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University Completes Its First PET/CT-Guided Interventional Puncture Procedure

From August 21 to 22, Professor Sun Long from the PET Center of the First Affiliated Hospital of Xiamen University was invited to the Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University for academic exchange, and on the following day provided on-site guidance for the hospital's first PET/CT-guided interventional puncture procedure. The successful completion of this procedure marks a new clinical practice milestone for the department in the field of interventional nuclear medicine. On August 21, Professor Sun Long delivered a special lecture titled "Exploration of Clinical Integrated Application of Diagnostic Nuclear Medicine and Interventional Nuclear Medicine Based on the PET Platform," focusing on how the PET platform extends from disease diagnosis and precise localization to interventional diagnosis and treatment. Drawing on clinical practice and typical cases, he introduced the application of interventional nuclear medicine in lesion...

2026-08-27